A large-scale trial of RTS,S – the world’s first malaria vaccine to provide partial protection – is due to commence in Malawi, Kenya and Ghana.
Browsing: Clinical Trial
ECCMID19: Suvratoxumab completes Phase II for treatment of Staphylococcus aureus in the New Drugs 4 Bad Bugs program
Collaborative research efforts have seen a novel monoclonal antibody, suvratoxumab, complete a Phase II trial targeted towards Staphylococcus aureus. This SAATELLITE study comes as the first clinical trial in the Innovative Medicines Initiative, formed to develop alternative medicines to combat antibiotic resistance.
A single, oral dose of antimalarial DSM265 has cleared seven volunteers of a Plasmodium falciparum infection, according to the trial from the Medicines for Malaria Venture.
Take a look at this month’s industry headlines including Priority Review for two antibacterial agents from Merck (NJ, USA), a clinical trial for a new malaria drug and the launch of omadacycline in the USA.
Some of the challenges with mass ivermectin administration could be addressed with new drugs or drug combinations with higher effect for the parasite – leading us to ask, what new treatments are currently in the clinical pipeline?
A first for clinical trials in the US as researchers from the University of California San Diego School of Medicine get US FDA approval to use intravenously-administered bacteriophage therapy in hopes of combatting resistant bacteria.
A new trial has begun in the Democratic Republic of Congo, aiming to collect robust data on the safety and efficacy of investigational Ebola therapeutics.
Concurrent major US and Canadian clinical trials prove probiotics to be ineffective in combatting gastroenteritis in children.
A Phase II, muti-center, randomized, open-label trial has reported that a novel oral antibiotic, zoliflodacin, is effective in the treatment of uncomplicated urogenital gonorrhea.
New data analysis of three clinical trials has suggested that a precision medicine approach could allow some pulmonary TB patients to have significantly shorter treatment periods.